Monday Morning Movers in Focus

The FDA has granted priority review for the supplemental new drug application (sNDA) for Vemurafenib Capsules USP 300 mg, a treatment for adult patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). Novo Nordisk’s Q4 earnings are expected to show revenue growth driven by strong sales of its diabetes treatments. Analysts forecast the company’s diabetes segment will see significant gains in the coming months. The Domino’s Pizza Inc. board has approved a share repurchase program aimed at returning capital to shareholders. The plan authorizes the purchase of up to $250 million worth of shares. A Phase III trial of Gilead Sciences’ Yescarta (axicabtagene ciloleucel) is currently enrolling patients. The treatment targets adults with certain types of blood cancers, including diffuse large B-cell lymphoma and primary central nervous system lymphoma. Monday’s Market Watch